fda semaglutide news Compound versions of GLP-1 drugs for weight loss halted by Semaglutide shortage ends as FDA

32,33 In addition to protein intake and exercise habits, several other lifestyle modifications may help the weight loss and maintenance efforts of those using GLP-1 medications

Mentis N, Vardarli I, Kthe LD et al (2011) GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) become more widely prescribed for weight loss, questions about nutrient depletion and vitamin requirements have increased

However, the level of pain can vary from person to person, and many individuals find the discomfort to be tolerable